A young Chinese prodigy determined to help his grandmother with Alzheimer’s invented an AI mini-computer to help her recognize family members and find the way home.
Nanodevices are the newest weapon in medicine’s growing arsenal to fight Alzheimer’s. They capture dangerous peptides before they can assemble to form Alzheimer’s plaques in the brain.
Research shows that lecanemab is the first drug ever to slow cognitive decline in Alzheimer’s. Learn more.
A certain protein in the blood can be used to predict the eventual appearance of Alzheimer’s. Will this allow for early intervention?
Eli Lilly Company’s TRAILBLAZER-ALZ 2 Phase 3 study shows that donanemab significantly slowed cognitive and functional decline in people with early symptomatic Alzheimer’s disease. Learn more.
A new form of Omega-3 has successfully increased DHA in the retina and reduced eye problems associated with Alzheimer’s-like processes.
The AlzoSure® Blood Test can catch Alzheimer’s two years before symptoms appear. Its development could not be more timely. With FDA approval of lecanemab for Alzheimer’s, this accurate and economical screening tool will dramatically assist patients most likely to benefit from early treatment.
BREAKTHROUGH: Researchers have developed a blood test that can predict the risk of future cognitive decline and Alzheimer’s. The test checks levels of a fragment
DIAGNOSIS: A highly sensitive blood test has reached the market that can identify whether it is likely a patient has amyloid plaques in the brain,
PROGRESS: ApoE4 is the best known “Alzheimer’s Gene”. Gladstone Institute scientists successfully changed the gene’s structure. This eliminated certain signs of Alzheimer’s, restored normal cell
A personal diary of a daughter with a medical background that chronicles her journey while caring for her father with Alzheimer’s, and gives the reader the gift of both perspectives, that of a loving daughter and the trained professional.
Scientists say restoring a brain protein, not removing amyloid plaques, should be the target of Alzheimer’s dementia therapies. The researchers said treatment might lie in normalizing the levels of a specific brain protein.
Did you know? Intellectual abilities are increased in the brain by an average 300% in most people ages 60-80.
People worry about becoming forgetful. Is it the first sign of Alzheimer’s or just the passing years? After all, forgetfulness is a normal part of aging. Check out these quick ways to tell the difference.
Researchers found in a study that people who developed dementia were more likely to have their credit rating drop at least two and a half years before the diagnosis. Some had problems managing their money up to six years before. Find out more.
Scientists say restoring a brain protein, not removing amyloid plaques, should be the target of Alzheimer’s dementia therapies. The researchers said treatment might lie in normalizing the levels of a specific brain protein.
Dietary iron is an essential element in the brain. That’s why it is critical to understand how it affects Alzheimer’s. Researchers used advanced X-ray techniques to take a giant step forward in understanding iron chemistry in amyloid plaque, the main culprit behind Alzheimer’s. Learn more about their exciting new insights.
No spam, only news and updates.
